Lurbinectedin is a drug used for the treatment of metastatic small cell lung cancer (SCLC) in adult patients who have progressed after platinum-based chemotherapy. According to the sources provided, there are some known contraindications to the use of lurbinectedin.

One of the primary contraindications to the use of lurbinectedin is hypersensitivity to the drug or any of its components. Patients who have a known allergy or hypersensitivity to lurbinectedin should not use the drug. In addition, the use of lurbinectedin is contraindicated in patients with severe hepatic impairment, as the drug is primarily metabolized in the liver [2].

Lurbinectedin is also contraindicated in patients with a history of long QT syndrome or uncontrolled electrolyte abnormalities, as it can cause QT prolongation and electrolyte imbalances. Patients with a history of cardiovascular disease or taking medications that can cause QT prolongation should use lurbinectedin with caution [3].

Furthermore, lurbinectedin should not be used in pregnant women or women who are breastfeeding, as it may cause harm to the fetus or infant [1]. It is important to note that these are not the only contraindications to the use of lurbinectedin, and patients should consult with their healthcare provider before using the drug.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf
[3] https://go.drugbank.com/drugs/DB12674